Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 15/20 | 0.75 |
| ▸ | GABRB3 | P28472 | 15/20 | 0.75 |
| ▸ | GABRA3 | P34903 | 14/20 | 0.75 |
| ▸ | GABRA5 | P31644 | 13/20 | 0.75 |
| ▸ | GABRA1 | P14867 | 8/20 | 0.56 |
| ▸ | ATR | Q13535 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4851113 | 0.87 | GABRG2 (0.60) | GABRG2GABRB3GABRA3GABRA5GABRA1 | |
| SCHEMBL4854386 | 0.87 | GABRG2 (0.56) | GABRG2GABRB3GABRA3GABRA5GABRA1 | |
| SCHEMBL23296289 | 0.86 | KMT2A (0.57) | GABRG2GABRB3GABRA3GABRA5GABRA1 | |
| SCHEMBL31663534 | 0.86 | KMT2A (0.57) | GABRG2GABRB3GABRA3GABRA5GABRA1 | |
| SCHEMBL4851447 | 0.84 | GABRG2 (0.70) | GABRG2GABRB3GABRA3GABRA5GABRA1 | |
| SCHEMBL31663620 | 0.77 | GABRG2 (0.67) | GABRG2GABRB3GABRA3GABRA5MEN1 | |
| SCHEMBL2652644 | 0.72 | GABRG2 (1.00) | GABRG2GABRB3GABRA3GABRA5GABRA1 | |
| SCHEMBL31663524 | 0.71 | GABRG2 (0.55) | GABRG2GABRB3GABRA3GABRA5ATR | |
| SCHEMBL2652318 | 0.71 | GABRG2 (0.62) | GABRG2GABRB3GABRA3GABRA5GABRA1 | |
| SCHEMBL2652546 | 0.71 | GABRG2 (0.58) | GABRG2GABRB3GABRA3GABRA5GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7381725-B2 | Pyridazine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LTD. (GB) | 2008-06-03 | — | — | US | claimed |
| US-20060148809-A1 | Pyridazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2006-07-06 | — | — | US | claimed |
| EP-1532136-A1 | PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2005-05-25 | — | — | EP | claimed |
| WO-2004014891-A1 | PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2004-02-19 | — | — | WO | claimed |
| US-7381725-B2 | Pyridazine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LTD. (GB) | 2008-06-03 | — | — | US | disclosed |
| US-20060148809-A1 | Pyridazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2006-07-06 | — | — | US | disclosed |
| EP-1532136-A1 | PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004014891-A1 | PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148809-A1 | Pyridazine derivatives as ligands for gaba receptors | GABRA5, GABRA3, GABRA2 | GABRG2 15/4885GABRB3 6/4885GABRA3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.